Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report

BACKGROUND: The advent of immunotherapies has ushered in a new era in the treatment of non-small cell lung carcinoma. Although immunotherapies are associated with improved clinical outcomes, studies report a median overall survival of 11 months with progression-free survival of 2.5 months with the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Boby, Jeffrey Mathew, Mohd Ghazali, Nurul Nadia, Mani, Anita, George, Mathew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635214/
https://www.ncbi.nlm.nih.gov/pubmed/36329437
http://dx.doi.org/10.1186/s13256-022-03593-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635214/
https://www.ncbi.nlm.nih.gov/pubmed/36329437
http://dx.doi.org/10.1186/s13256-022-03593-3

Ejemplares similares